Inovio’s DNA-Based Immunotherapy Lands Speedy FDA Nod for Rare Type of Tumor

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 02 Nov, 20:45 UTC

Inovio’s Voceryq will compete with a Precigen product that last year became the first FDA-approved drug for recurrent respiratory papillomatosis, or RRP. While the two immunotherapies carry the same $460,000 list price, Inovio executives claim their product has another competitive advantage. The…

science

Sources

• T2Inovio’s DNA-Based Immunotherapy Lands Speedy FDA Nod for Rare Type of TumorFierce Biotech / Fierce Healthcare / MedCity / GEN02 Nov, 20:45